<DOC>
	<DOCNO>NCT01011998</DOCNO>
	<brief_summary>The aim study test effect combination valproate combination imatinib aim achieve maximal molecular response primary goal .</brief_summary>
	<brief_title>A Study Imatinib Valproic Acid Patients With Chronic Myelogenous Leukemia ( CML )</brief_title>
	<detailed_description>The aim study test effect combination valproate combination imatinib aim achieve maximal molecular response primary goal . Briefly , patient CML take imatinib find plateau level bcr-abl transcript eligible participate study . Valproate add imatinib , subsequent bcr-abl transcript monitor see addition valproate produce reduction . Patients monitor efficacy toxicity .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>All patient , 18 year age old , diagnosis CML . Patients must life expectancy least 12 week . Patients must ECOG performance status 02 . Patients must sign informed consent . Patients adequate hepatic function total bilirubin &lt; 2 mg/dl SGOT SGPT &lt; two time upper limit normal , adequate renal function define serum creatinine &lt; 1.5 x upper limit normal . Patients CML chronic phase imatinib first line therapy fulfill follow criterion : The patient least two test quantitative reverse transcriptase polymerase chain reaction ( RTPCR ) bcrabl ( peripheral blood bone marrow aspirate ) . The result test demonstrate relative plateau effect imatinib detect level transcript ( i.e . le Â½ log difference last two value ) . Note : Patients eligible recent study great previous study value . The last two quantitative RTPCR study least 3 month apart . The patient receive least 9 month imatinib since diagnosis CML . The patient tolerate imatinib without grade 3 great toxicity . Pregnant woman nurse mother eligible trial . Patients child bear potential must use adequate contraception . Patients may receive concurrent chemotherapy radiation therapy trial . Patients severe medical problem uncontrolled diabetes mellitus cardiovascular disease active infection eligible trial . Patients hypersensitivity valproic acid , derivative , component formulation . Patients hepatic disease significant impairment , urea cycle disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>CML</keyword>
	<keyword>Chronic Myelogenous leukemia</keyword>
	<keyword>INST 0901</keyword>
	<keyword>imatinib</keyword>
	<keyword>valproic acid</keyword>
	<keyword>Gleevec</keyword>
</DOC>